Solute carrier transporter superfamily (SLC)

The Solute Carrier (SLC) transporter superfamily is the largest group of membrane transport proteins in the human genome, comprising over 400 members organized into 65 families (Hediger et al., 2013, Nature Reviews Drug Discovery). These proteins are primarily located on the plasma membrane and organelle membranes, where they facilitate the movement of a diverse array of solutes, including ions, nucleotides, amino acids, vitamins, and drugs, across biological membranes (Lin et al., 2015, Nature Reviews Drug Discovery). Unlike ABC transporters, SLCs typically function through facilitated diffusion or secondary active transport, utilizing ion gradients rather than direct ATP hydrolysis to drive substrate movement (Pizzagalli et al., 2021, MedChemComm). They play vital roles in physiological processes such as nutrient absorption, waste excretion, and neurotransmitter signaling (Cesar-Razquin et al., 2015, Cell). In clinical medicine, SLC transporters are pivotal therapeutic targets and key determinants of drug disposition (Rask-Andersen et al., 2014, Nature Reviews Drug Discovery). For example, inhibitors of SLC5A2 (SGLT2) are standard treatments for type 2 diabetes, while SLC6A4 (SERT) is the primary target for selective serotonin reuptake inhibitors (SSRIs) in treating depression (Nigam, 2015, Nature Reviews Drug Discovery). Mutations or dysregulation in these transporters are associated with various metabolic diseases, such as gout or Hartnup disease, and they are frequently involved in clinically relevant drug-drug interactions, particularly those involving OAT and OCT families in the kidney and liver (Zamek-Gliszczynski et al., 2018, Clinical Pharmacology & Therapeutics).

Other names

Solute carrier proteinsSLC transportersSLC superfamilySolute carriers

Inhibition of substrate transport (competitive or non-competitive), substrate mimicry (acting as a 'prodrug' or false substrate), and modulation of electrochemical gradients to alter solute flux.